On August 19, Boston Scientific rose 3.21% in regular trading, trading at $52.41/share with turnover of $163 million.

The rally was driven by the announcement that Boston Scientific's new-generation thermal vapor therapy device Rezum EVO received approval from China's National Medical Products Administration for the treatment of benign prostatic hyperplasia. China has become one of the first markets globally to approve this product. The device represents the latest upgrade to the Rezum thermal vapor treatment platform, featuring an enhanced user interface and improved portability suited for outpatient and day-surgery settings. Rezum EVO will be manufactured locally at Boston Scientific's Shanghai Lingang factory, exclusively supplying the Chinese market.

The approval underscores Boston Scientific's accelerating product localization strategy in one of the world's largest healthcare markets, potentially expanding its urology segment revenue base in the region.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)